Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open Labeled Single Ascending Dose Followed by Multiple Dose Safety and Pharmacokinetic Study of HBI-002 Carbon Monoxide Oral Liquid Drug Product in Healthy Adult Volunteers

Next Previous
Search
Trial Profile

A Phase 1 Open Labeled Single Ascending Dose Followed by Multiple Dose Safety and Pharmacokinetic Study of HBI-002 Carbon Monoxide Oral Liquid Drug Product in Healthy Adult Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carbon monoxide (Primary)
  • Indications Parkinson's disease; Vaso-occlusive crisis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Hillhurst Biopharmaceuticals

    • Most Recent Events

    • 23 May 2023 According to Hillhurst Biopharmaceuticals media release, the treatment and follow-up of final study subject completed, Hillhurst anticipates top line results from the completed trial in Q2 2023.
    • 23 May 2023 Status changed from recruiting to completed as per Hillhurst Biopharmaceuticals media release.
    • 30 Sep 2022 Planned End Date changed from 1 Oct 2022 to 1 Feb 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top